Literature DB >> 7541969

CFTR expression and organ damage in cystic fibrosis.

E F Tizzano1, M Buchwald.   

Abstract

The cloning of the defective gene in cystic fibrosis (CFTR) is the most important step to date toward understanding the pathogenesis of the disease and developing novel therapeutic strategies. Although many studies have provided insights into the molecular defects and knowledge of the expression and role of the gene, the basic defect and its pathogenesis are still unclear. We hypothesize that organ damage in cystic fibrosis is the result of a combination of at least three main factors: the genotype (the type of mutation that alters the function of the cystic fibrosis transmembrane regulator [CFTR]), the rate of CFTR-mediated chloride secretion in the epithelium of each organ (inferred from the level of expression of the gene), and the anatomical and physiologic characteristics of the affected organs (the size and contents of the ducts). Confirmation of this hypothesis should allow a better understanding of the pathogenesis of the disease and help prevent organ damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541969     DOI: 10.7326/0003-4819-123-4-199508150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

Review 1.  Women with cystic fibrosis and their potential for reproduction.

Authors:  F P Edenborough
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

2.  WNK4 regulates apical and basolateral Cl- flux in extrarenal epithelia.

Authors:  Kristopher T Kahle; Ignacio Gimenez; Hatim Hassan; Frederick H Wilson; Robert D Wong; Biff Forbush; Peter S Aronson; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

3.  WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl- -transporting epithelia.

Authors:  Keith A Choate; Kristopher T Kahle; Frederick H Wilson; Carol Nelson-Williams; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-08       Impact factor: 11.205

4.  Contraception and pregnancy in cystic fibrosis.

Authors:  J G Thorpe-Beeston
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

5.  Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.

Authors:  Elena K Schneider; Felisa Reyes-Ortega; John W Wilson; Tom Kotsimbos; Dominic Keating; Jian Li; Tony Velkov
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-10-24       Impact factor: 3.205

Review 6.  Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?

Authors:  E K Schneider; F Reyes-Ortega; J Li; T Velkov
Journal:  Clin Pharmacol Ther       Date:  2016-11-23       Impact factor: 6.875

Review 7.  CFTR, mucins, and mucus obstruction in cystic fibrosis.

Authors:  Silvia M Kreda; C William Davis; Mary Callaghan Rose
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

8.  Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.

Authors:  Steffie E M Vonk; Marloes van der Meer-Vos; Lieuwe D J Bos; Anne H Neerincx; Christof J Majoor; Anke-Hilse Maitland-van der Zee; Ron A A Mathôt; E Marleen Kemper
Journal:  Ther Drug Monit       Date:  2021-08-01       Impact factor: 3.681

9.  Predictors of sinonasal disease onset, progression, and severity in pediatric cystic fibrosis patients.

Authors:  Michael S Weinstock; Amber D Shaffer; Amanda L Stapleton
Journal:  Am J Otolaryngol       Date:  2021-03-31       Impact factor: 2.873

10.  Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.

Authors:  Serena Schippa; Valerio Iebba; Floriana Santangelo; Antonella Gagliardi; Riccardo Valerio De Biase; Antonella Stamato; Serenella Bertasi; Marco Lucarelli; Maria Pia Conte; Serena Quattrucci
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.